211 related articles for article (PubMed ID: 35650266)
1. Persister state-directed transitioning and vulnerability in melanoma.
Chauvistré H; Shannan B; Daignault-Mill SM; Ju RJ; Picard D; Egetemaier S; Váraljai R; Gibhardt CS; Sechi A; Kaschani F; Keminer O; Stehbens SJ; Liu Q; Yin X; Jeyakumar K; Vogel FCE; Krepler C; Rebecca VW; Kubat L; Lueong SS; Forster J; Horn S; Remke M; Ehrmann M; Paschen A; Becker JC; Helfrich I; Rauh D; Kaiser M; Gul S; Herlyn M; Bogeski I; Rodríguez-López JN; Haass NK; Schadendorf D; Roesch A
Nat Commun; 2022 Jun; 13(1):3055. PubMed ID: 35650266
[TBL] [Abstract][Full Text] [Related]
2. Melanoma activation of 3-o-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase.
Sánchez-del-Campo L; Tárraga A; Montenegro MF; Cabezas-Herrera J; Rodríguez-López JN
Mol Pharm; 2009; 6(3):883-94. PubMed ID: 19358568
[TBL] [Abstract][Full Text] [Related]
3. Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.
Vogel FCE; Bordag N; Zügner E; Trajkovic-Arsic M; Chauvistré H; Shannan B; Váraljai R; Horn S; Magnes C; Thomas Siveke J; Schadendorf D; Roesch A
J Invest Dermatol; 2019 Dec; 139(12):2506-2516.e10. PubMed ID: 31229500
[TBL] [Abstract][Full Text] [Related]
4. Directed phenotype switching as an effective antimelanoma strategy.
Sáez-Ayala M; Montenegro MF; Sánchez-Del-Campo L; Fernández-Pérez MP; Chazarra S; Freter R; Middleton M; Piñero-Madrona A; Cabezas-Herrera J; Goding CR; Rodríguez-López JN
Cancer Cell; 2013 Jul; 24(1):105-19. PubMed ID: 23792190
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.
Sánchez-del-Campo L; Chazarra S; Montenegro MF; Cabezas-Herrera J; Rodríguez-López JN
J Cell Biochem; 2010 Aug; 110(6):1399-409. PubMed ID: 20564235
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes.
Eberle J; Weitmann S; Thieck O; Pech H; Paul M; Orfanos CE
J Invest Dermatol; 1999 Jun; 112(6):925-32. PubMed ID: 10383740
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a pair of synthetic tea-catechin-derived epimers: synthesis, antifolate activity, and tyrosinase-mediated activation in melanoma.
Sáez-Ayala M; Sánchez-del-Campo L; Montenegro MF; Chazarra S; Tárraga A; Cabezas-Herrera J; Rodríguez-López JN
ChemMedChem; 2011 Mar; 6(3):440-9. PubMed ID: 21302360
[TBL] [Abstract][Full Text] [Related]
8. H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity.
He R; Xhabija B; Gopi LK; Kurup JT; Xu Z; Liu Z; Kidder BL
Oncogene; 2022 May; 41(21):2958-2972. PubMed ID: 35440714
[TBL] [Abstract][Full Text] [Related]
9. PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91.
Grabacka M; Placha W; Urbanska K; Laidler P; Płonka PM; Reiss K
Pigment Cell Melanoma Res; 2008 Jun; 21(3):388-96. PubMed ID: 18444964
[TBL] [Abstract][Full Text] [Related]
10. The histone demethylase KDM5b/JARID1b plays a role in cell fate decisions by blocking terminal differentiation.
Dey BK; Stalker L; Schnerch A; Bhatia M; Taylor-Papidimitriou J; Wynder C
Mol Cell Biol; 2008 Sep; 28(17):5312-27. PubMed ID: 18591252
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon-gamma response in melanocytic cells.
Chhabra Y; Yong HXL; Fane ME; Soogrim A; Lim W; Mahiuddin DN; Kim RSQ; Ashcroft M; Beatson SA; Ainger SA; Smit DJ; Jagirdar K; Walker GJ; Sturm RA; Smith AG
Pigment Cell Melanoma Res; 2018 Jan; 31(1):51-63. PubMed ID: 28755520
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma.
Park BJ; Brown CK; Hu Y; Alexander HR; Horti J; Raje S; Figg WD; Bartlett DL
Hum Gene Ther; 1999 Apr; 10(6):889-98. PubMed ID: 10223723
[TBL] [Abstract][Full Text] [Related]
13. Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.
Sánchez-del-Campo L; Rodríguez-López JN
Int J Cancer; 2008 Nov; 123(10):2446-55. PubMed ID: 18729182
[TBL] [Abstract][Full Text] [Related]
14. Pirin is a prognostic marker of human melanoma that dampens the proliferation of malignant cells by downregulating JARID1B/KDM5B expression.
Penas C; Arroyo-Berdugo Y; Apraiz A; Rasero J; Muñoa-Hoyos I; Andollo N; Cancho-Galán G; Izu R; Gardeazabal J; Ezkurra PA; Subiran N; Alvarez-Dominguez C; Alonso S; Bosserhoff AK; Asumendi A; Boyano MD
Sci Rep; 2023 Jun; 13(1):9561. PubMed ID: 37308689
[TBL] [Abstract][Full Text] [Related]
15. Sequence-dependent cross-resistance of combined radiotherapy plus BRAF
Shannan B; Matschke J; Chauvistré H; Vogel F; Klein D; Meier F; Westphal D; Bruns J; Rauschenberg R; Utikal J; Forschner A; Berking C; Terheyden P; Dabrowski E; Gutzmer R; Rafei-Shamsabadi D; Meiss F; Heinzerling L; Zimmer L; Livingstone E; Váraljai R; Hoewner A; Horn S; Klode J; Stuschke M; Scheffler B; Marchetto A; Sannino G; Grünewald TGP; Schadendorf D; Jendrossek V; Roesch A
Eur J Cancer; 2019 Mar; 109():137-153. PubMed ID: 30721788
[TBL] [Abstract][Full Text] [Related]
16. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Roesch A; Vultur A; Bogeski I; Wang H; Zimmermann KM; Speicher D; Körbel C; Laschke MW; Gimotty PA; Philipp SE; Krause E; Pätzold S; Villanueva J; Krepler C; Fukunaga-Kalabis M; Hoth M; Bastian BC; Vogt T; Herlyn M
Cancer Cell; 2013 Jun; 23(6):811-25. PubMed ID: 23764003
[TBL] [Abstract][Full Text] [Related]
17. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.
Matatall KA; Agapova OA; Onken MD; Worley LA; Bowcock AM; Harbour JW
BMC Cancer; 2013 Aug; 13():371. PubMed ID: 23915344
[TBL] [Abstract][Full Text] [Related]
18. Melanocyte differentiation marker gp75, the brown locus protein, can be regulated independently of tyrosinase and pigmentation.
Vijayasaradhi S; Doskoch PM; Wolchok J; Houghton AN
J Invest Dermatol; 1995 Jul; 105(1):113-9. PubMed ID: 7615964
[TBL] [Abstract][Full Text] [Related]
19. Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma.
Jordan AM; Khan TH; Osborn HM; Photiou A; Riley PA
Bioorg Med Chem; 1999 Sep; 7(9):1775-80. PubMed ID: 10530924
[TBL] [Abstract][Full Text] [Related]
20. Role of microphthalmia transcription factor in regulation of melanocyte differentiation marker TRP-1.
Fang D; Setaluri V
Biochem Biophys Res Commun; 1999 Mar; 256(3):657-63. PubMed ID: 10080955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
